Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Funding Programs
Pilot & Feasibility
Summer Student
External Funding Programs
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
FUNDING PROGRAMS
Pilot & Feasibility
Summer Student
External Funding Programs
CONTACT
PARTICIPANT AREA
Login
Request Account
▹
DiaComp Funded Abstracts
▹
Pilot & Feasibility
▹
Funding Programs
Pilot & Feasibility Program Application Abstract
HP-MRI organ imaging to identify the risk of DKA with SGLT2 inhibitors in DM
Waheed Shabbir
(San Francisco, CA)
Pilot & Feasibility Program
SGLT2 inhibitors are important antidiabetic drugs with a broad range of effects. Many studies including the FDA warned that the use of SGLT2 inhibitors can increase the risk of diabetic ketoacidosis. The number of DKA incidence increased markedly worldwide, with one estimate suggesting that as many as 145,000 cases/year with T1DM in North America. T1DM patients are more likely to develop SGLT2 inhibitors associated with DKA due to insulin deficiency, which are amongst the most common causes of DKA. Indeed, it has been shown that the incidence of DKA in individuals with T1DM is higher than T2DM who are exposed to SGLT2 inhibitors. To date, no medical commodity available for non-invasive imaging of DKA. Therefore, a non-invasive real-time tissue interrogation technique is critically needed. To fill this gap, we have developed a non-invasive real-time HP-MRI organ imaging technique. Indeed, using HP-MRI we have detected divergent metabolic differences in gluconeogenic tissue between models of T1 and T2DM. In this project, our laboratory is interested in studying whether we can image the DKA non-invasively in vivo, in DM models. Using two contrasting DM rat models we are particularly interested to answer the following questions: (1) Whether we can image the ketone body turnover in kidney and in the liver following SGLT2 inhibitors treatment in real-time in vivo. (2) Whether the kidneys and livers of animals treated with SGLT2 inhibitors show increased ketone body turnover; and (3) Whether SGLT2-mediated gluconeogenesis signals go hand in hand with ketogenesis
Data for this report has not yet been released.
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an external advisor to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
Internet Explorer
Google Chrome
FireFox
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!